Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory [Yahoo! Finance]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Yahoo! Finance
Aldeyra Therapeutics shares were trading at $4.15 when this thesis was published, vs. closing price of $5.38 on Aug 29. A biotechnologist in a white lab coat manipulating genes in a laboratory. Aldeyra Therapeutics, a biotechnology company specializing in the development of innovative treatments for immune-mediated diseases, stands out in the industry for its focus on RASP (reactive aldehyde species) inhibition. RASP, known for its role in inflammatory processes, is a novel target in treating conditions like dry eye disease (DED) and other immune disorders. The company's lead product, reproxalap, is an eye drop formulation designed to inhibit RASP, positioning Aldeyra as a potential leader in the DED market, a condition affecting millions globally. See Also 33 Most Important AI Companies You Should Pay Attention To Reproxalap's journey has been marked by significant milestones and challenges. Initially, the drug showed strong promise in clinical trials, particularly in its abi
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option AgreementBusiness Wire
- Aldeyra Therapeutics to Participate in the Jefferies London Healthcare ConferenceBusiness Wire
- Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 MeetingBusiness Wire
- Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease [Seeking Alpha]Seeking Alpha
ALDX
Earnings
- 11/7/24 - In-Line
ALDX
Sec Filings
- 11/18/24 - Form 8-K
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- ALDX's page on the SEC website